{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:07:08Z","timestamp":1760954828536},"reference-count":31,"publisher":"Wiley","issue":"s3","license":[{"start":{"date-parts":[[2006,4,27]],"date-time":"2006-04-27T00:00:00Z","timestamp":1146096000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2006,7]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> The aim of treatment of von Willebrand's disease (VWD) is to correct the dual defect of haemostasis, i.e. the abnormal platelet adhesion due to reduced and\/or dysfunctional von Willebrand factor (VWF) and the abnormal coagulation expressed by low levels of factor VIII (FVIII). Desmopressin (DDAVP) is the treatment of choice for type 1 VWD because it can induce release of normal VWF from cellular compartments. Prospective studies on biological response versus clinical efficacy of DDAVP in VWD type 1 and 2 are in progress to further explore its benefits and limits as therapeutic option. In type 3 and in severe forms of type 1 and 2 VWD, DDAVP is not effective and for these patients plasma virally inactivated concentrates containing VWF and FVIII are the mainstay of treatment. Several intermediate\u2010 and high\u2010purity VWF\/FVIII concentrates are available and have been shown to be effective in clinical practice (bleeding and surgery). New VWF products almost devoid of FVIII are now under evaluation in clinical practice. Although thrombotic events are rare in VWD patients receiving repeated infusions of concentrates, there is some concern that sustained high FVIII levels may increase risk of postoperative venous thromboembolism. Dosage and timing of VWF\/FVIII administrations should be planned to keep FVIII level between 50 and 150 U\/dL. Appropriate dosage and timing in repeated infusions are also very important in patients exposed to secondary long term prophylaxis for recurrent bleedings.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2006.01273.x","type":"journal-article","created":{"date-parts":[[2006,4,28]],"date-time":"2006-04-28T08:36:36Z","timestamp":1146213396000},"page":"152-158","source":"Crossref","is-referenced-by-count":19,"title":["Von Willebrand's disease: clinical management"],"prefix":"10.1111","volume":"12","author":[{"given":"A. B.","family":"FEDERICI","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"CASTAMAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"THOMPSON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"BERNTORP","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,4,27]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"1","volume-title":"Proceedings of a Nordic von Willebrand symposium","author":"Lee CA","year":"1999"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra040403"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2004.10.001"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)91197-7"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V66.4.796.796"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-103-1-6"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2072"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0268-960X(91)90032-8"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.1996.tb00018.x"},{"key":"e_1_2_5_11_2","first-page":"94","article-title":"von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment","volume":"88","author":"Castaman G","year":"2003","journal-title":"Haematologica"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200311000-00010"},{"key":"e_1_2_5_13_2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1055\/s-0038-1653816","article-title":"No influence of blood group on the responsiveness to desmopressin in type I \u201cplatelet normal\u201d von Willebrand's disease","volume":"73","author":"Castaman G","year":"1995","journal-title":"Thromb Haemost"},{"key":"e_1_2_5_14_2","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1016\/S0021-9258(18)42852-9","article-title":"Impaired cellular transport produced by a subset of type IIA von Willebrand disease mutations","volume":"267","author":"Lyons SE","year":"1992","journal-title":"J Biol Chem"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb05127.x"},{"key":"e_1_2_5_16_2","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1055\/s-0037-1613769","article-title":"Von Willebrand disease type 2 M \u2018\u2018Vicenza\u2019\u2019 in Italian and German patients: identification of the first candidate mutation (G3864A; R1205H) in 8 families","volume":"83","author":"Schneppenheim R","year":"2000","journal-title":"Thromb Haemost"},{"key":"e_1_2_5_17_2","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1055\/s-0037-1614019","article-title":"An additional candidate mutation (G2470A; M740I) in the original families with von Willebrand disease type 2 M Vicenza and the G3864A (R1205H) mutation","volume":"84","author":"Castaman G","year":"2000","journal-title":"Thromb Haemost"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.1.180"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.11.4243"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01706.x"},{"key":"e_1_2_5_21_2","first-page":"32","article-title":"Willebrand factor for treating patients with von Willebrand disease","volume":"1","author":"Thompson AR","year":"2005","journal-title":"Haematol Rep"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mbc.0000167658.85143.49"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01435.x"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00893.x"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2005.11.010"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2000.02507.x"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00991.x"},{"key":"e_1_2_5_28_2","volume-title":"Report on the Universal Data Collection Program","author":"Centers for Disease Control and Prevention","year":"2004"},{"key":"e_1_2_5_29_2","first-page":"546","article-title":"International survey of patients with von Willebrand disease and angiodysplasia","volume":"79","author":"Fressineaud E","year":"1993","journal-title":"Thromb Haemost"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mbc.0000167659.23262.18"},{"key":"e_1_2_5_31_2","volume-title":"Long\u2010term Prophylaxis in VWD. The Swedish Experience","author":"Berntorp E"},{"key":"e_1_2_5_32_2","doi-asserted-by":"crossref","first-page":"507a","DOI":"10.1182\/blood.V106.11.1782.1782","article-title":"Secondary long\u2010term prophylaxis in severe patients with von Willebrand disease: an Italian cohort study","volume":"106","author":"Federici AB","year":"2005","journal-title":"Blood"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2006.01273.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2006.01273.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T04:22:39Z","timestamp":1695702159000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2006.01273.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,27]]},"references-count":31,"journal-issue":{"issue":"s3","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["10.1111\/j.1365-2516.2006.01273.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2006.01273.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,27]]}}}